DNAPrint Pharmaceuticals

DNAPrint Pharmaceuticals was a biotechnology company specializing in genomics-based products for the consumer, forensic, and pharmaceutical markets. The company was best known for its "AncestryByDNA" test, which provided estimates of genetic heritage, and its "DNAWitness" forensic tool used to determine the physical characteristics of suspects from DNA samples. In the pharmaceutical sector, DNAPrint focused on pharmacogenomics to develop personalized medicine, notably advancing PT-401, a recombinant erythropoietin variant for treating anemia. The company's business model integrated diagnostic testing with drug development, aiming to use genetic markers to predict patient response to specific therapies. Despite its innovative approach to genetic ancestry and drug response modeling, the company faced significant financial difficulties and ceased operations in the late 2000s.